keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Verapamil (CP-16533-1) 是一种钙通道阻滞剂,是一种口服有效的 P-gp 抑制剂。Verapamil 抑制 CYP3A4,可用于治疗高血压、心律失常和心绞痛的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 298 | 现货 | ||
25 mg | ¥ 483 | 现货 | ||
50 mg | ¥ 690 | 现货 | ||
100 mg | ¥ 973 | 现货 | ||
200 mg | ¥ 1,430 | 现货 | ||
500 mg | ¥ 2,390 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 287 | 现货 |
产品描述 | Verapamil (CP-16533-1) is a calcium channel blocker and an orally active and effective inhibitor of P-gp. Verapamil inhibits CYP3A4 and can be used in studies about the treatment of high blood pressure, heart arrhythmias, and angina research. |
体外活性 | Verapamil inhibits the EverFluor FL Verapamil (EFV) uptake by TR-iBRB2 cells with an IC50 of 98.0 μM in a concentration-dependent manner[1]. |
体内活性 | Verapamil (1 mg/kg;i.v.) significantly decreases the incidence of ventricular arrhythmias including premature ventricular contractions (PVC), ventricular tachycardia (VT) and ventricular fibrillation (VF) for 45-min coronary artery occlusion. Total arrhythmia scores are significantly increased when the heart is subjected to ischemia. Verapamil (1 mg/kg) significantly prevents the enhancement of total arrhythmia scores induced by ischemia[3]. Verapamil(oral) is useful for the prophylaxis of atrioventricular reentry tachycardia, and also in modulating the atrioventricular nodal response in atrial fibrillation[4]. |
别名 | NSC 135784, 维拉帕米, NSC-135784, CP-16533-1, (±)-Verapamil |
分子量 | 454.6 |
分子式 | C27H38N2O4 |
CAS No. | 52-53-9 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (208.97 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1997 mL | 10.9987 mL | 21.9974 mL | 54.9934 mL |
5 mM | 0.4399 mL | 2.1997 mL | 4.3995 mL | 10.9987 mL | |
10 mM | 0.22 mL | 1.0999 mL | 2.1997 mL | 5.4993 mL | |
20 mM | 0.11 mL | 0.5499 mL | 1.0999 mL | 2.7497 mL | |
50 mM | 0.044 mL | 0.22 mL | 0.4399 mL | 1.0999 mL | |
100 mM | 0.022 mL | 0.11 mL | 0.22 mL | 0.5499 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Verapamil 52-53-9 Membrane transporter/Ion channel Metabolism Neuroscience P450 Calcium Channel P-gp inhibit NSC 135784 Pgp antiarrhythmic CYP3A4 Cytochrome P450 Palbociclib CYPs pressure ABCB1 维拉帕米 angina Multidrug resistance protein 1 Ca2+ channels NSC-135784 lysosomotropic MDR1 Ca channels CP-16533-1 Cluster of differentiation 243 high NSC135784 Inhibitor P-glycoprotein CD243 (±)-Verapamil blood inhibitor